Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics, a multidisciplinary initiative to advance scientific investigation, translational research, and clinical care approaches for patients with RAS-driven cancers.
Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.
